Skip to main content
. Author manuscript; available in PMC: 2024 Feb 28.
Published in final edited form as: Hepatol Int. 2019 Mar 5;13(3):270–276. doi: 10.1007/s12072-019-09941-8

Fig. 2.

Fig. 2

Mean activated ± 95% confidence interval (CI) for percentage of CD8+ T cells with an activated HLA-DR+ and CD38+ phenotype at pre-DAA therapy (PRE), DAA therapy (DAA), end of treatment (EOT), sustained virologic response (SVR), and post-SVR year 1–2 (YR 1–2) among HCV (n = 161) and HIV/HCV (n = 69) patients treated with DAA therapy and achieved SVR